Maternal plasma soluble endoglin at 11–13 weeks' gestation in pre‐eclampsia

@article{Foidart2010MaternalPS,
  title={Maternal plasma soluble endoglin at 11–13 weeks' gestation in pre‐eclampsia},
  author={Jean-Michel Foidart and Carine Munaut and Frederic Chantraine and Ranjit Akolekar and Kypros H. Nicolaides},
  journal={Ultrasound in Obstetrics and Gynecology},
  year={2010},
  volume={35}
}
To examine the performance of screening for pre‐eclampsia (PE) by a combination of maternal factors, soluble endoglin (sEng), pregnancy associated plasma protein‐A (PAPP‐A), placental growth factor (PlGF) and uterine artery lowest pulsatility index (L‐PI) at 11–13 weeks' gestation. 
View on Wiley
fetalmedicine.com
91 Citations
Highly Influential Citations
3
Background Citations
20
Methods Citations
3
Results Citations
2

91 Citations

Citation Type

Citation Type

Longitudinal changes in maternal soluble endoglin and angiopoietin‐2 in women at risk for pre‐eclampsia
To investigate longitudinal changes in maternal plasma levels of soluble endoglin (sEng) and angiopoietin‐2 (Ang‐2) in pregnant women who develop pre‐eclampsia (PE) and gestational hypertension (GH).
Serum hyperglycosylated human chorionic gonadotrophin at 14–17 weeks of gestation does not predict preeclampsia
Low first‐trimester serum concentrations of hyperglycosylated human chorionic gonadotrophin (hCG‐h) predict later preeclampsia. We studied whether serum hCG‐h at 14–17 weeks of pregnancy also…
Prediction of early, intermediate and late pre‐eclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks
TLDR
To develop models for prediction of pre‐eclampsia (PE) based on maternal factors and biophysical and biochemical markers at 11–13 weeks' gestation using data from routine and sham pregnancies.
New directions in the prediction of pre‐eclampsia
TLDR
Recent research into strategies for the prediction of pre‐eclampsia, including the use of maternal risk factors, mean maternal arterial pressure, ultrasound parameters and biomarkers are reviewed, with the most promising strategies involve multiparametric approaches.
Early Predictors of Pre-eclampisa
TLDR
Pre-eclampsia is a major reason for maternal and perinatal mortality and morbidity worldwide inflicting 15% of all direct maternal deaths and a multiple increase in perinnatal mortality with induced prematurity being the most perpetrators.
Maternal serum endoglin as an early marker of pre-eclampsia in high-risk patients
TLDR
Estimation of serum soluble endoglin at gestational week 13 could be used as a sensitive screening test for women at high risk of developing pre-eclampsia prior to onset of its clinical manifestations, which could potentially improve the outcome of pregnancy.
A prospective study on first trimester prediction of ischemic placental diseases
The objective of the study is to assess the predictive power of mean uterine artery pulsatility index (UtA PI), maternal serum placental growth factor (PlGF) and placenta associated plasma protein A…
Maternal Characteristics, Mean Arterial Pressure and Serum Markers in Early Prediction of Preeclampsia
TLDR
First-trimester MAP, PAPP-A, ADAM12, and PlGF combined with maternal characteristics and MAP are promising markers in the risk assessment of PE, especially for EO-PE complicated by SGA.
First trimester hyperglycosylated human chorionic gonadotrophin in serum - a marker of early-onset preeclampsia.
Pregnancy-associated plasma protein A (PAPP-A) and preeclampsia.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 46 REFERENCES
Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre‐eclampsia
TLDR
To investigate the potential value of maternal serum placental growth factor (PlGF) in first‐trimester screening for pre‐eclampsia (PE) and its role in pregnancy development, a large number of women were enrolled for screening.
Uterine artery Doppler at 11 + 0 to 13 + 6 weeks in the prediction of pre‐eclampsia
TLDR
To determine the performance of screening for pre‐eclampsia (PET) by maternal characteristics and uterine artery pulsatility index (PI) at 11 + 0 to 13 + 6 weeks' gestation, a large number of women with high‐risk pregnancies are surveyed.
Maternal plasma soluble fms‐like tyrosine kinase‐1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia
To investigate the maternal plasma concentration of soluble fms‐like tyrosine kinase‐1 (sFlt‐1) and free vascular endothelial growth factor (free‐VEGF) at 11 to 13 weeks of gestation in patients…
Endoglin, PlGF and sFlt‐1 as markers for predicting pre‐eclampsia
TLDR
Endoglin, PlGF and sFlt‐1 might be used as markers for predicting pre‐eclampsia, but sFolt‐1: PlGF seems to be more accurate.
First‐trimester screening for trisomy 21 by free beta‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐A: impact of maternal and pregnancy characteristics
To use multiple regression analysis to define the contribution of maternal variables that influence the measured concentration of free beta‐human chorionic gonadotropin (β‐hCG) and…
Hypertensive disorders in pregnancy: screening by uterine artery Doppler at 11–13 weeks
TLDR
To examine the performance of screening for hypertensive disorders in pregnancy by a combination of the maternal factor‐derived a‐priori risk with the uterine artery pulsatility index (PI), the mean PI of the two arteries, the highest PI or the lowest PI is used.
Role of uterine artery Doppler in interpreting low PAPP‐A values in first‐trimester screening for Down syndrome in pregnancies at high risk of impaired placentation
  • I. Herraiz, E. A. López-Jiménez, +4 authors A. Galindo
  • Medicine, Biology
    Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • 2009
TLDR
The aim of this study was to determine whether high UtA resistance plays a role in explaining low PAPP‐A levels in the absence of aneuploidies.
Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction.
TLDR
Pregnancy with IUGR, but without maternal symptoms, was characterized by elevated sEng concentrations in circulation, although this finding is less pronounced when compared with preeclampsia, sEng seems to be involved in different clinical manifestations of placental pathology.
Maternal Circulating Levels of Activin A, Inhibin A, sFlt-1 and Endoglin at Parturition in Normal Pregnancy and Pre-Eclampsia
TLDR
Labour in pre-eclamptic women increases the levels of sFlt-1 and activin A, and increase in the maternal levels of these factors in labour could predict and/or contribute to the maternal syndrome postpartum.
First-Trimester Uterine Artery Doppler and Serum Pregnancy-Associated Plasma Protein-A in Preeclampsia and Chromosomal Defects
TLDR
The uterine artery PI at 11–13 weeks may be useful in distinguishing between low PAPP-A due to trisomy 21 and early PE in pregnancies with fetal aneuploidies and those that developed preeclampsia.
...
1
2
3
4
5
...